Kinin-mediated coronary nitric oxide production contributes to the therapeutic action of angiotensin-converting enzyme and neutral endopeptidase inhibitors and amlodipine in the treatment in heart failure

Journal of Pharmacology and Experimental Therapeutics

Volumn 288, Issue 2, 1999, Pages 742-751

  Zhang, Xiaoplng ^a   Recchia, Fabio A ^a   Bernstein, Robert ^a   Xu, Xiaobin ^a   Nasjletti, Alberto ^a   Hintze, Thomas H ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 DICHLOROISOCOUMARIN; AMLODIPINE; BRADYKININ; BRADYKININ B2 RECEPTOR ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRILAT; ENKEPHALINASE INHIBITOR; ICATIBANT; KININ; KININOGEN; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRITE; PHOSPHORAMIDON; RAMIPRILAT; SERINE PROTEINASE INHIBITOR; THIORPHAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY; DOG; DRUG EFFECT; DRUG MECHANISM; HEART FAILURE; ISOLATED ARTERY; NONHUMAN; PRIORITY JOURNAL;

AMLODIPINE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; CORONARY VESSELS; CYSTEINE PROTEINASE INHIBITORS; DOGS; ENALAPRILAT; GLYCOPEPTIDES; HEART FAILURE, CONGESTIVE; KININOGENS; KININS; NITRIC OXIDE; PROTEASE INHIBITORS; RAMIPRIL; RECEPTOR, BRADYKININ B2; RECEPTORS, BRADYKININ; THIORPHAN; VASODILATOR AGENTS;

EID: 0033030241     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Coric P, Turcaud S, Meudal H, Roqes BP and Fournie-Zaluski MC (1996) Optimal recognition of neutral endopeptidase and angiotensin-converting enzyme active sites by mercatoacyldipeptidase as a means to design potent dual inhibitors. J Med Chem 39:1210-1219.
2. Dragovic T, Minshall R, Jackman HL, Wang LX and Erdos EG (1996) Kininase II-type enzymes. Diabetes 45(Suppl 1):S34-S37.
3. Drexler H, Hayoz D, Munzel T, Just H, Zelis R and Brunner HR (1994) Endothelial dysfunction in chronic heart failure: Experimental and clinical studies. Arzneim Forsch 44(Suppl I):455-458.
4. 2+ channels. Br J Pharmacol 117: 1035-1040.
5. Erdos EG and Skidgel RA (1989) Neutral endopeptidase 2.4.1 (enkephalinase) and related regulators of peptide hormones. FASEB J 3:145-151.
6. Erdos EG (1990) Some old and some new ideas on kinin metabolism. J Cardiovasc Pharmacol 15(Suppl 6):S20-S24.
7. Fink CA, Qiao Y, Berry CJ, Sakane Y, Ghai RD and Trapani AJ (1995) New α-thiol dipeptide dual inhibitors of angiotensin-I converting enzyme and neutral endopeptidase EC 3.4.24.11. J Med Chem 38:5023-5030.
8. Gerritsen ME and Printz MP (1981) Sites of prostaglandin synthesis in the bovine heart and isolated bovine coronary microvessels. Circ Res. 49:1152-1163.
9. Graf K, Grafe M, Bossaller C, Niehus J, Schulz KD, Auch-Schwelk W and Fleck E (1993) Degradation of bradykinin by neutral endopeptidase (EC 3.4.24.11) in cultured human endothelial cells. Eur J Clin Chem Clin Biochem 31:267-272.
10. Graf K, Koehne P, Grafe M, Zhang M, Auch-Sshwelk W and Fleck E (1995) Regulation and differential expression of neutral endopeptidase 24.11 in human endothelial cells. Hypertension 26:230-235.
11. Grafford JT, Skidgel RA, Erdos EG and Hersh LB (1983) Human kidney "enkephalinase", a neutral endopeptidase that cleaves action peptidase. Biochemistry 22:3265-3271.
12. 2+ and stimulates prostaglandin synthesis by cultured bovine aortic endothelial cells. Horm Metab Res 29:38-42.
13. Katz SD, Schwarz M, Yuen J and Lejemtel TH (1993) Impaired acetylcholine-mediated vasodilation in patients with congestive heart failure: role of endothelium-derived vasodilating and vasoconstricting factors. Circulation 88:55-61.
14. Kerr MA and Kenny AJ (1974) The purification and specificity of a neutral endopeptidase from rabbit kidney brush border. Biochem J 137:477-488
15. Linz W, Wiemer G, Gohlke P, Unger T and Scholkens BA (1995) Contribution of kinins to the cardiovascular action of angiotensin-converting enzyme inhibitors. Pharmacol Rev 47:25-49.
16. Lliceto S (1997) Left ventricular dysfunction: which role for calcium antagonists? Eur Heart J 18(Suppl A):A87-A91.
17. Llorens-Cortest C, Huang H, Vicart P, Gasc JM, Paulin D and Corvol P (1992) Identification and characterization of neutral endopeptidase in endothelial cells from venous or arterial origins. J Biol Chem 267:14012-14018.
18. Lyons D, Webster J and Benjamin N (1994) The effect of antihypertensive therapy on responsiveness to local intra-arterial N-monomethyl-L-arginine in patients with essential hypertension. J Hypertension 12:1047-1052.
19. Messerli FH (1996) What, if anything, is controversial about calcium antagonists? Am J Hypertens 9:177s-181s.
20. Moncada S, RMJ Palmer and EA Higgs (1991) Nitric oxide, physiology, pathophysiology and pharmacology. Pharm Rev 43:109-142.
21. Mugge A, Peterson T and Harrison DG (1991) Release of nitrogen oxide from cultured bovine aortic endothelial cells is not impaired by calcium channel antagonists. Circulation 83:1404-1409.
22. Murdoch D and Heel RC (1991) Amlodipine. a review of its pharmacodynamic and pharmacokinetics properties, and therapeutic use in cardiovascular disease. Drugs 41:478-505.
23. Nolly HL, Carbini LA, Scicli G, Carretero OA and Scicli AG (1994) A local Kallikreinkinin system is present in rat hearts. Hypertension 23:919-923.
24. Nolly HL, Carretero OA and Scicli AG (1993) Kallikrein release by vascular tissue. Am J Physiol 265:H1209-H1214.
25. Packer M, O'Connor CM, Ghali JK, Pressler ML, Carson PE, Belkin RN, Miller AB, Neuberg GW, Frid D, Wertheimer JH, Cropp AB and Demets DL (1996) Effects of amlodipine on motbidity and mortality in severe chronic heart failure. N Engl J Med 335:1107-1114.
26. Scholkens BA (1996) Kinins in the cardiovascular system. Immunopharmacology 33:209-216.
27. Schwelk WA, Kuchenbuch C, Claus M, Walther B, Bossaller C Friedel N, Graf K, Graf M and Fleck E (1993) Local regulation of vascular tone by bradykinin and angiotensin converting enzyme inhibitors. Eur Heart J 14(Suppl I):154-160.
28. Skidgel RA (1992) Bradykinin-degrading enzymes: Structure, function, distribution, and potential roles in cardiovascular pharmacology. J Cardiovasc Pharmacol 20(Suppl 9):S4-S9.
29. Soleilhac JM, Sucas E, Turcuad VS, Michel JB, Ficheux D, Fournie-zaluski MC and Roques BP (1992) A 94-kDa protein, identified as neutral endopeptidase-24.11, can inactivate atrial natriuretic peptide in the vascular endothelium. Mol Pharmacol 41:609-614.
30. Treasure CB, Vita JA, Cox DA, Fish RD, Gordon JB, Mudge GH, Colucci WS, St John Sutton MG, Selwyn AP, Alexander RW and Ganz P (1990) Endothelium-dependent dilation of coronary microvasculature is impaired in dilated cardiomyopathy. Circulation 81:772-779.
31. Trippodo NC, Balkruhna CP and Fox M (1995a) Repression of angiotensin II and potentiation of bradykinin contribute to the synergistic effects of dual metalloprotease inhibition in heart failure. J Pharmacol Exp Ther 272:619-627.
32. Trippodo NC, Robl JA, Asaad MM, Bird E, Panchal BC, Schaeffer TR, Fox M, Giancarli MR and Cheung HS (1995b) Cardiovascular effects of the novel dual inhibitor of neutral endopeptidase and angiotensin-converting enzyme BMS-182657 in experimental hypertension and heart failure. J Pharmacol Exp Ther 275:745-752.
33. Ura N, Carretero OA and Erdos EG (1987) Role of renal endopeptidase 24.11 in kinin metabolism in vitro and in vivo. Kidney Int 32:507-513.
34. Waeber B and Brunner HR (1997) Combination antihypertensive therapy: Does it have a role in rational therapy? Am J Hypertens 10:1318-1378.
35. Wang J, Seyedi N, Xu X, Wolin MS and Hintze TH (1994) Defective endothelium-mediated control of coronary circulation in conscious dogs after heart failure. Am J Physiol 268:H670-H680.
36. Wiemer G, Scholkens BA and Linz W (1994) Endothelial protection by converting enzyme inhibitors. Cardiovasc Res 28:166-172.
37. Yang XP, Liu YH, Peterson E and Carretero OA (1997) Effect of neutral endopeptidase 24.11 inhibition on myocardial ischemia/reperfusion injury: The role of kinins. J Cardiovasc Pharmacol 29:250-256.
38. Zhang X and Hintze TH (1998b) Amlodipine releases nitric oxide from canine coronary microvessels: an unexpected mechanism of action of a calcium channel-blocking agent. J Cardiovasc Pharmacol 31:623-629.
39. Zhang X, Nasjletti A, Xu X and Hintze TH (1998a) Neutral endopeptidase and angiotensin converting enzyme inhibitors increase nitric oxide production in isolated canine coronary microvessels by a kinin-dependent mechanism. J Cardiovasc Pharmacol 31:623-629.
40. Zhang X, Xie Y, Nasjletti A, Xu X, Wolin MS and Hintze TH (1997) ACE inhibitors stimulate nitric oxide production to modulate myocardial oxygen consumption. Circulation 95:176-182.